DNAJB6:一个保护神经退行症的守护者
Jónvá Hentze1, Anna Gelman2, Tomasz Brudek3
1Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Neural regeneration research
|June 19, 2025
概括
DNAJ同类子家族B成员6 (DNAJB6) 护卫器可以防止粉样蛋白聚集,这些蛋白质与诸如亨廷顿病,帕金森病和阿尔茨海默病等神经退行性疾病有关. 这篇评论探讨了DNAJB6的保护作用和治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 蛋白质生物化学 蛋白质生物化学
背景情况:
- 粉样蛋白聚合是神经退行性疾病的关键驱动因素.
- DNAJ同类子家族B成员6 (DNAJB6) 伴侣在防止蛋白质聚合方面表现有前途.
研究的目的:
- 审查大脑中已知的DNAJB6的保护功能.
- 探索DNAJB6与Hsp70的相互作用及其在防止粉样蛋白聚合中的作用.
- 讨论DNAJB6表达的失调及其治疗潜力.
主要方法:
- 在神经退行性疾病模型中对DNAJB6功能研究的文献综述.
- 对DNAJB6抗聚合能力的体外和体内数据的分析.
- 对大脑组织中DNAJB6表达的临床数据的检查.
主要成果:
- DNAJB6 阻止了多重胺蛋白 (亨廷顿病),α-synuclein (帕金森病) 和粉样蛋白 (阿尔茨海默病) 的聚合.
- DNAJB6与Hsp70相互作用,增强其伴侣活动.
- 在受影响的大脑组织中观察到DNAJB6表达的失调.
结论:
- DNAJB6 是对大脑中粉样蛋白聚合的重要保护因素.
- DNAJB6代表了神经退行性疾病的有希望的可用药物的目标.
- 进一步研究DNAJB6的机制和治疗应用是有必要的.
关键词:
在DNAJB6中使用.聚合方式 聚合方式 聚合方式陪伴者 (chaperones) 是指一个陪伴者.临床组织临床组织.人类大脑 人类大脑神经退行症的神经退行症神经退行性疾病的神经退行性疾病治疗目标是治疗的目标.更多相关视频
08:44Quantitative Cell Biology of Neurodegeneration in Drosophila Through Unbiased Analysis of Fluorescently Tagged Proteins Using ImageJ
Published on: August 3, 2018
10.1K
10:00In Vivo Forward Genetic Screen to Identify Novel Neuroprotective Genes in Drosophila melanogaster
Published on: July 11, 2019
9.6K
相关概念视频
Neurogenesis and Regeneration of Nervous Tissue
1.1K
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
1.1K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Glial Cells
89.3K
Overview
89.3K
The Blood-brain Barrier
49.0K
Overview
49.0K
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
